MedTrace Logo

Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination

NCT07133802 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6680

Last updated 2025-08-21

No results posted yet for this study

Summary

A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination

Conditions

  • Prevention of Influenza

Interventions

BIOLOGICAL

Placebo Group

Each human dose: 0.2 mL

BIOLOGICAL

Test Group

Each human dose is 0.2 mL

Sponsors & Collaborators

  • Hubei Provincial Center for Disease Control and Prevention

    collaborator OTHER

  • Center for Disease Control and Prevention, Fujian

    collaborator OTHER

  • Zhejiang Provincial Center for Disease Control and Prevention

    collaborator OTHER_GOV

  • Changchun BCHT Biotechnology Co.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-31
Primary Completion
2026-03-31
Completion
2026-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07133802 on ClinicalTrials.gov